Sigyn Therapeutics, Inc. (OTCMKTS:SIGY – Get Free Report) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 1,994 shares. Currently, 0.4% of the company’s shares are short sold. Based on an average daily volume of 13,955 shares, the short-interest ratio is presently 0.1 days.
Sigyn Therapeutics Stock Down 8.6%
Shares of OTCMKTS SIGY opened at $0.03 on Friday. Sigyn Therapeutics has a 12 month low of $0.01 and a 12 month high of $2.00. The company has a market cap of $70,612.00, a price-to-earnings ratio of -0.01 and a beta of -0.04. The business has a fifty day simple moving average of $0.03 and a 200-day simple moving average of $0.12.
About Sigyn Therapeutics
Sigyn Therapeutics, Inc is a biotechnology and medical device company focused on developing therapeutic solutions for cancer and pathogen-associated diseases. The company’s primary technology is designed to address conditions in which harmful pathogens and excessive inflammatory signaling contribute to disease progression.
Its lead product candidate, Sigyn Therapy, is an extracorporeal blood-purification technology intended to remove circulating pathogens and inflammatory cytokines from a patient’s blood.
Further Reading
- Five stocks we like better than Sigyn Therapeutics
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Sigyn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigyn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
